Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

143
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
143
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

390
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
390
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

192
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
192
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

235
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bacterial taxa associated with lung cancer cases in Southeast Asians: a pilot case-control study.

Cellular oncology (Dordrecht, Netherlands)·2026
Same author

Targeting Inflammation in Bronchiectasis.

Drugs·2026
Same author

Single-bacterial cell insights into mechanisms of ceftriaxone resistance in Neisseria subflava.

Nature communications·2026
Same author

Lower airway dysbiosis in nontuberculous mycobacteria-positive bronchiectasis is associated with neutrophil extracellular trap-predominant severe phenotypes.

American journal of respiratory and critical care medicine·2026
Same author

Human airway organoids for bacterial-host interaction studies: methods, insights and translational promise.

Thorax·2026
Same author

Gut-lung microbial dynamics with lumacaftor/ivacaftor in children with cystic fibrosis: a prospective multicenter study.

Pediatric research·2026
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

480

The bronchiectasis microbiome: current understanding and treatment implications.

Jayanth Kumar Narayana1, Micheál Mac Aogáin2,3, Philip M Hansbro4

  • 1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.

Current Opinion in Pulmonary Medicine
|November 4, 2024
PubMed
Summary
This summary is machine-generated.

The respiratory microbiome is linked to bronchiectasis, offering new diagnostic and treatment possibilities. Understanding these microbial communities can lead to better patient outcomes.

More Related Videos

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.2K
Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
07:38

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

2.3K

Related Experiment Videos

Last Updated: Jun 8, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

480
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
06:57

The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections

Published on: May 8, 2017

9.2K
Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
07:38

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

2.3K

Area of Science:

  • Respiratory Medicine
  • Microbiology
  • Genomics

Background:

  • Bronchiectasis is an under-recognized condition with significant heterogeneity.
  • Recent studies emphasize the role of the respiratory microbiome in bronchiectasis phenotypes.
  • Advances in sequencing technologies enable detailed microbiome analysis.

Purpose of the Study:

  • To review recent progress in understanding the bronchiectasis microbiome.
  • To explore the potential of microbiome analysis in clinical decision-making for bronchiectasis.
  • To highlight opportunities for diagnosis, stratification, and personalized interventions.

Main Methods:

  • Review of recent large-scale, multicentre, and longitudinal clinical studies.
  • Analysis of findings from classical microbiology and holistic microbiome sequencing.
  • Integration of microbiome data with clinical and biological datasets.

Main Results:

  • Bronchiectasis exhibits diverse microbiome profiles, reflecting disease heterogeneity.
  • Key microbial markers include Pseudomonas aeruginosa and Haemophilus influenza.
  • Holistic analysis reveals associations with other bacterial taxa, fungi, viruses, and their interactions.

Conclusions:

  • The bronchiectasis microbiome is a critical emerging area of research.
  • Microbiome insights have significant implications for understanding and treating bronchiectasis.
  • Further integration of microbiome data promises to improve patient outcomes.